Format

Send to

Choose Destination
J Control Release. 2017 Oct 10;263:120-131. doi: 10.1016/j.jconrel.2017.03.017. Epub 2017 Mar 11.

MR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound.

Author information

1
Department of Biomedical Engineering, University of Virginia, 415 Lane Road Building MR5, Charlottesville, VA 22908, United States.
2
Department of Ophthalmology, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD 21287, United States; Center for Nanomedicine, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD 21287, United States; Department of Biochemistry, PMAS-Arid Agriculture University, Shamsabad, Muree Road, Rawalpindi, Pakistan.
3
Department of Ophthalmology, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD 21287, United States; Center for Nanomedicine, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD 21287, United States.
4
Department of Radiology and Medical Imaging, University of Virginia, 480 Ray C Hunt Drive, Charlottesville, VA 22908, United States.
5
Department of Biomedical Engineering, University of Virginia, 415 Lane Road Building MR5, Charlottesville, VA 22908, United States. Electronic address: rprice@virginia.edu.

Abstract

Systemically administered chemotherapeutic drugs are often ineffective in the treatment of invasive brain tumors due to poor therapeutic index. Within gliomas, despite the presence of heterogeneously leaky microvessels, dense extracellular matrix and high interstitial pressure generate a "blood-tumor barrier" (BTB), which inhibits drug delivery and distribution. Meanwhile, beyond the contrast MRI-enhancing edge of the tumor, invasive cancer cells are protected by the intact blood-brain barrier (BBB). Here, we tested whether brain-penetrating nanoparticles (BPN) that possess dense surface coatings of polyethylene glycol (PEG) and are loaded with cisplatin (CDDP) could be delivered across both the blood-tumor and blood-brain barriers with MR image-guided focused ultrasound (MRgFUS), and whether this treatment could control glioma growth and invasiveness. To this end, we first established that MRgFUS is capable of significantly enhancing the delivery of ~60nm fluorescent tracer BPN across the blood-tumor barrier in both the 9L (6-fold improvement) gliosarcoma and invasive F98 (28-fold improvement) glioma models. Importantly, BPN delivery across the intact BBB, just beyond the tumor edge, was also markedly increased in both tumor models. We then showed that a CDDP loaded BPN formulation (CDDP-BPN), composed of a blend of polyaspartic acid (PAA) and heavily PEGylated polyaspartic acid (PAA-PEG), was highly stable, provided extended drug release, and was effective against F98 cells in vitro. These CDDP-BPN were delivered from the systemic circulation into orthotopic F98 gliomas using MRgFUS, where they elicited a significant reduction in tumor invasiveness and growth, as well as improved animal survival. We conclude that this therapy may offer a powerful new approach for the treatment invasive gliomas, particularly for preventing and controlling recurrence.

KEYWORDS:

Blood-brain barrier; Blood-tumor barrier; Cisplatin; Focused ultrasound; Glioma; Nanoparticle

PMID:
28288892
PMCID:
PMC5593770
[Available on 2018-10-10]
DOI:
10.1016/j.jconrel.2017.03.017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center